Mid Coast Hospital

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia5 trials
• Colorectal cancer3 trials
• Lung cancer3 trials
• Melanoma3 trials
• Ovarian cancer3 trials
• Chronic lymphocytic leukaemia2 trials
• Gastric and oesophageal cancer2 trials
• Metastatic breast cancer2 trials
• Multiple myeloma2 trials
• Prostate cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• Bladder cancer1 trial
• and 7 more

Phase

• Phase 23 trials
• Phase 32 trials

Status

• Recruiting7 trials
• Active, not recruiting1 trial

Lead sponsor

• National Cancer Institute (NCI)5 trials
• Alliance for Clinical Trials in Oncology1 trial
• NRG Oncology1 trial
• Wake Forest University Health Sciences1 trial

Running trials

• Recruiting

  Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  NCT06672146· Phase 2· National Cancer Institute (NCI)· Source

  Contact: Pamela Egan (principal investigator)

• Recruiting

  Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

  NCT06418204· Wake Forest University Health Sciences· Source

  Contact: Scot C Remick (principal investigator)

• Recruiting

  Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  NCT06317649· Phase 2· National Cancer Institute (NCI)· Source

  Contact: Pamela Egan (principal investigator)

• Recruiting

  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  NCT05564390· Phase 2· National Cancer Institute (NCI)· Source

  Contact: Pamela Egan (principal investigator)

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

  Contact: Michael Auster (principal investigator)

• Recruiting

  Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  NCT05334069· Alliance for Clinical Trials in Oncology· Source

  Contact: Leslie S. Bradford (principal investigator)

• Recruiting

  Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  NCT04269902· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Andrew Rogers (principal investigator)

• Active, not recruiting

  National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia4 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Colorectal cancer2 recruiting
• Lung cancer2 recruiting
• Melanoma2 recruiting
• Ovarian cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Bladder cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting